Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | KDR | P35968 | 13/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610597 | 1.00 | SCN9A (0.40) | SCN9AKDRHCRTR2TRPC3TRPC6 | |
| SCHEMBL16754703 | 0.94 | KDR (0.36) | SCN9AKDRTRPC3TRPC6 | |
| SCHEMBL16754712 | 0.94 | KDR (0.36) | SCN9AKDRTRPC3TRPC6 | |
| SCHEMBL16611019 | 0.90 | KDR (0.38) | KDRTRPC3TRPC6 | |
| SCHEMBL16610807 | 0.85 | KDR (0.38) | KDR | |
| SCHEMBL16772657 | 0.85 | KDR (0.38) | KDR | |
| Fumaric Acid SCHEMBL16754736 | 0.83 | KDR (0.37) | KDRTRPC3TRPC6 | |
| Maleic Acid SCHEMBL16754735 | 0.83 | KDR (0.37) | KDRTRPC3TRPC6 | |
| SCHEMBL16610621 | 0.82 | KDR (0.40) | KDRTRPC3TRPC6 | |
| SCHEMBL16772700 | 0.82 | JAK2 (0.36) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | claimed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | claimed |
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | NIPPON SHINYAKU CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9580413-B2 | Substituted pyrrolidines as ROS tyrosine kinase inhibitors | NIPPON SHINYAKU CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143722-A1 | SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS | ROS1, NOX4, NOX3 | SCN9A 2592/4885KDR 301/4885HCRTR2 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.